Bishnoi R, Shah C, Blaes A, et al. - In patients aged ≥ 65 years-old with metastatic non-small cell lung cancer newly diagnosed between 2013 and 2015, researchers examined if cardiovascular toxicity resulted from adding immune checkpoint inhibitors to traditional chemotherapy. They used SEER-Medicare datasets, which represent 34% of the US population, to conduct this retrospective study. Among 6,405 included patients, 5,730 received chemotherapy and only 675 received chemotherapy and immune checkpoint inhibitors. Analyses yielded reassuring results concerning the safety of adding immune checkpoint inhibitors to chemotherapy, indicating that its addition did not result in raised cardiovascular toxicity, but instead resulted in lower hazards. In patients who received immune checkpoint inhibitors with chemotherapy, the hazard ratio for all cardiovascular toxicity was 0.81. An increased risk was seen in patients above 75 years, with comorbidities and pre-existing heart disease.